首页|期刊导航|医学新知|1990-2021年全球与中国老年人群代谢功能障碍相关脂肪性肝病的疾病负担分析

1990-2021年全球与中国老年人群代谢功能障碍相关脂肪性肝病的疾病负担分析OA

Disease burden of metabolic dysfunction-associated steatotic liver disease in the elderly population globally and in China from 1990 to 2021

中文摘要英文摘要

目的 分析 1990-2021 年全球及中国老年人群代谢功能障碍相关脂肪性肝病(MASLD)的疾病负担变化趋势及影响因素,并预测其未来发展趋势.方法 从全球疾病负担 2021 数据库中提取全球、中国及 5 个社会人口学指数(SDI)地区 60 岁及以上人群 MASLD 的患病和伤残调整生命年(DALY)数据.采用 Joinpoint 回归分析计算 1990-2021 年年龄标化患病率(ASPR)和年龄标化 DALY 率(ASDR)的平均年度变化百分比(AAPC),并根据不同年龄段和性别进行亚组分析.采用三因素分解模型量化老龄化、人口增长及流行病学变化对疾病负担改变的相对影响,同时运用贝叶斯年龄-时期-队列模型预测 2022-2035 年老年人群 MASLD 疾病负担的发展趋势.结果 2021 年全球与中国老年总体人群 MASLD 患病人数分别为 36 639.84 万例、9 891.68 万例,较 1990 年分别增加 176.40%、230.71%;DALYs 分别为 183.47 万人年、23.41 万人年,较 1990 年分别增加 139.52%、127.06%.1990-2021 年全球老年总体人群 MASLD 的 ASPR[AAPC=0.67%,95%CI(0.62%,0.72%)]、ASDR[AAPC=0.20%,95%CI(0.06%,0.34%)]均呈显著上升趋势,但中国老年总体人群 MASLD 的 ASPR[AAPC=0.65%,95%CI(0.55%,0.75%)]呈上升趋势,ASDR[AAPC=-0.49%,95%CI(-0.92%,-0.06%)]呈下降趋势.性别亚组分析显示,1990 年和 2021 年全球与中国老年女性人群的患病人数、DALYs数均高于同时期的男性人群.1990-2021 年高-中、低 SDI 地区老年人群 MASLD 的 ASDR 整体上均呈显著下降趋势,2021 年 5 个 SDI 地区老年人群 MASLD 的患病人数和 DALYs 数较 1990 年均有所增加.2021 年全球 60~64 岁年龄老年人群 MASLD 患病人数和 DALYs 数占比最高,而中国则均为65~69 岁年龄组.分解分析表明,人口增长是不同地区 MASLD 疾病负担增加的主要影响因素,且对中国 DALYs 数增加的贡献度(122.09%)最大.预测模型显示,2035 年全球老年总体人群 MASLD 的患病人数和 DALYs 数较 2021 年将分别增加 65.80%、43.11%,而中国将分别增加 104.95%、24.78%.结论 全球及中国老年人群中 MASLD 的疾病负担依然沉重,且预计在未来将持续增加.建议在推广健康生活方式的基础上,积极采取多学科综合管理方法,针对老年 MASLD 患者实施有效干预,同时加大特效药物的研发力度,以减轻该疾病相关的负担.

Objective To analyze the changing trend and influencing factors of the disease burden of older adults with metabolic dysfunction-associated steatotic liver disease(MASLD)globally and in China from 1990 to 2021,and to predict its future trend.Methods Data on the prevalence and disability-adjusted life years(DALYs)of MASLD among individuals aged 60 years and older from the Global Burden of Disease(GBD)2021 database were extracted for a global context,China,and five socio-demographic index(SDI)regions.Joinpoint regression analysis was employed to calculate the average annual percent change(AAPC)in the age-standardized prevalence(ASPR)and DALY rates(ASDR)from 1990 to 2021,and the subgroup analyses were conducted by age and gender.A three-factor decomposition model was used to quantify the relative impacts of aging,population growth,and epidemiological change on the changes in disease burden,while a Bayesian age-period-cohort model was applied to predict the trend in disease burden of older adults with MASLD from 2022 to 2035.Results The number of MASLD patients in the global and Chinese elderly populations was 366,398,400 cases and 98,916,800 cases in 2021,respectively,representing an increase of 176.40%and 230.71%compared to 1990.The number of DALYs was 1,834,700 person-years and 234,100 person-years,showing increases of 139.52%and 127.06%,respectively.During the period from 1990 to 2021,ASPR[AAPC=0.67%,95%CI(0.62%,0.72%)]and ASDR[AAPC=0.20%,95%CI(0.06%,0.34%)]of MASLD in the global elderly population exhibited a significant upward trend.ASPR[AAPC=0.65%,95%CI(0.55%,0.75%)]of MASLD in the elderly population in China showed a significantly upward trend,while ASDR[AAPC=-0.49%,95%CI(-0.92%,-0.06%)]showed a significantly downward trend.Subgroup analyses by gender indicated that in both 1990 and 2021,the number of prevalence and DALYs in the elderly female populations were higher than those in the corresponding male populations globally and in China.Additionally,while the ASDR of MASLD among the elderly in high-middle and low SDI regions regions showed significant downward trends from 1990 to 2021,the number of patients and DALYs across the five SDI regions increased in 2021 compared to 1990.The 60~64 age group accounted for the highest proportion of case numbers and DALYs among the global elderly population with MASLD in 2021,whereas the 65~69 age group ranked the first in China.Decomposition analysis revealed that population growth was the primary influencing factor for the increase in disease burden of MASLD across all areas,contributing the most(122.09%)to the increase in DALYs in China.The prediction model indicated that by 2035,the number of cases and DALYs in the global elderly population would increase by 65.80%and 43.11%,respectively,compared to 2021,while in China,the increases would be 104.95%and 24.78%,respectively.Conclusion The disease burden of MASLD in the elderly populations globally and in China remains substantial and is expected to continue increasing in the future.It is recommended to promote healthy lifestyle practices while actively adopting a multidisciplinary management approach for elderly MASLD patients and enhancing the research and development of effective drugs to alleviate the burden associated with this disease.

张强;陈政涛;丁韵涵;柯立鑫;李洁韵;荀杨芹;卢存存;赵晓晓;王海博;徐鹏;王雅星;赵信科;刘璠;李嘉丽;何涛

河南中医药大学第一附属医院脾胃肝胆科(郑州 450000)中国人民解放军93811部队/兰空机关医院中医科(兰州 730000)承德医学院附属医院南院区检验科(河北 承德 067000)格罗宁根大学医学中心儿科学实验室(荷兰格罗宁根 9713GZ)上海中医药大学中医学院(上海 201203)中国医学科学院北京协和医学院群医学及公共卫生学院(北京 100730)甘肃中医药大学中西医结合研究所(兰州 730101)山东中医药大学附属医院老年医学中心(济南 250014)甘肃中医药大学附属医院重症医学科(兰州 730000)中国中医科学院中国医史文献研究所(北京 100700)中国中医科学院中医临床基础医学研究所(北京 100700)甘肃中医药大学中西医结合研究所(兰州 730101)甘肃中医药大学中西医结合研究所(兰州 730101)甘肃中医药大学中西医结合研究所(兰州 730101)甘肃省康复中心医院脊髓损伤康复科(兰州 730000)

医药卫生

代谢功能障碍相关脂肪性肝病非酒精性脂肪性肝病老年人疾病负担预测模型

Metabolic dysfunction-associated steatotic liver diseaseNon-alcoholic fatty liver diseaseOlder adultDisease burdenPrediction model

《医学新知》 2026 (4)

428-437,中插9-中插11,13

河南省中医药科学研究专项课题(2024ZY2046)河南省科技研发计划联合基金(优势学科培育类)项目(242301420112)

10.12173/j.issn.1004-5511.202506178

评论